Hansa Biopharma to Participate in Three Upcoming Investor Conferences

LUND, Sweden, Aug. 21, 2019 /PRNewswire/ -- Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that the Company's management team will participate in the following upcoming investor conferences: